HC Wainwright & Co. Maintains Buy on Aethlon Medical, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino maintains a Buy rating on Aethlon Medical (NASDAQ:AEMD) but lowers the price target from $23 to $10.
March 04, 2024 | 1:48 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Aethlon Medical's price target was reduced from $23 to $10 by HC Wainwright & Co., although the Buy rating was maintained.
The reduction in price target by a reputable analyst firm like HC Wainwright & Co. could lead to a negative short-term sentiment among investors, potentially causing a decrease in AEMD's stock price. However, maintaining a Buy rating indicates underlying confidence in the company's long-term prospects.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100